870063-18-6

Upstream product

• 353-83-3 1,1,1-trifluoro-2-iodoethane 
• 147460-41-1 2-bromo-5-fluorophenol 
• 6226-25-1 2,2,2-trifluoroethyl trifluoromethanesulphonate 
• 348-57-2 2,4-difluorobromobenzene 
• 75-89-8 2,2,2-trifluoroethanol 

Downstream Products

• 1403329-90-7 1-bromo-4-(methylsulfanyl)-2-(2,2,2-trifluoroethoxy)benzene 
• 1403330-66-4 2-(4-fluorophenyl)-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide 
• 1403329-91-8 1-bromo-4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)benzene 
• 1426252-07-4 C₃₄H₂₉BrF₄NiOP₂ 
• 1426252-08-5 C₃₅H₂₉BrF₆NiOP₂ 
• 1426252-15-4 C₄₂H₃₇ClF₄NiO₃P₂ 
• 1426252-16-5 C₄₃H₃₇ClF₆NiO₃P₂ 
• 1426252-11-0 C₄₄H₃₅BrF₄NiOP₂ 
• 1426252-12-1 C₄₅H₃₅BrF₆NiOP₂ 
• 1443763-91-4 6-(4-aminophenyl)-N-[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl][1,2,4]triazolo[1,5-α]pyridin-2-amine 
• 1443763-90-3 tert-butyl [4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-α]pyridin-6-yl)phenyl]carbamate 
• 1443763-70-9 (-)-2-(4-fluorophenyl)-3-hydroxy-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl] propanamide 
• 1443763-69-6 2-(4-fluorophenyl)-3-hydroxy-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]-propanamide 
• 1443763-62-9 (2R)-2-(4-fluorophenyl)-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-α]pyridin-6-yl)phenyl]propanamide 

Relevant academic research and scientific papers

METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to methods o f preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS

The present invention relates to substituted triazolopyridine compounds of general formula (I), in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER

The present invention relates to novel compounds showing an inhibitory effect on Mps-1 kinase, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to prodrug derivatives of Mps-1 kinase inhibitors, processes for their preparation, and their use for the treatment and/or prophylaxis of diseases.

Accelerating Ni(ii) precatalyst initiation using reactive ligands and its impact on chain-growth polymerizations

Nickel(ii) complexes with varying reactive ligands, which were designed to selectively accelerate the initiation rate without influencing the propagation rate in the chain-growth polymerization of π-conjugated monomers, were investigated. Precatalysts with electronically varied reacting groups led to faster initiation rates and narrower molecular weight distributions. Computational studies revealed that the reductive elimination rates are largely modulated by the ability of the two reacting arenes to stabilize the increasing electron density on the catalyst during reductive elimination. Overall, these studies provide insight into a key mechanistic step of cross-coupling reactions (reductive elimination) and highlight the importance of initiation in controlled chain-growth polymerizations.

SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS

The present invention relates to substituted triazolopyndine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

TRIAZOLOPYRIDINES

The present invention relates to triazolopyridine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said com

Regioselective SNAr reactions of substituted difluorobenzene derivatives: practical synthesis of fluoroaryl ethers and substituted resorcinols

In this Letter, we describe a practical and highly selective method for the preparation of fluoroaryl ethers and differentially substituted resorcinol derivatives. This synthetic strategy relies on a selective SNAr of substituted difluorobenzen

Regioselectivity of fluorine substitution by alkoxides on unsymmetrical difluoroarenes

An efficient approach to unsymmetrical halogenated resorcinol diethers has been developed. This synthesis consists of two subsequent nucleophilic aromatic substitutions (SNAr) of unsymmetrical difluoroarenes by alkoxides. The novelty of this ap